Drug lookup
Drug reference

didanosine

Antiretroviral

Antiretroviral
CDSCO approved
EXCRETION
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
not curated
Top interactionssee all 12
  • TenofovirContraindicatedTextbookG&G 14e · p1245-1266
  • AllopurinolSevereDatabaseDDInter
  • BexaroteneSevereDatabaseDDInter
  • DolutegravirSevereDatabaseDDInter

Mechanism

Not yet extracted

Indications

HIV infection (use has declined due to higher toxicity)

Dosing

Adult
400 mg/day (for > 60 kg BW), 250 mg/day (< 50 kg BW) 1 hour before or 2 hour after meals.

Pharmacokinetics

Half-life
1 to 1.5 hr
Bioavailability
38 ± 15%
Protein binding
<5%
Excretion
36 ± 9%

Side effects

Common
diarrhoeaabdominal paindry mouthnausea
Serious
  • peripheral (stocking and glove) neuropathy (major dose-related toxicity, may be irreversible)
  • acute pancreatitis (rarely)

Drug interactions

Tenofovir
Contraindicated
Textbook

Increased exposure to didanosine, potentially leading to increased toxicity.

The two drugs should not be used together.

Source: G&G 14e · p1245-1266

Allopurinol
Severe
Database

Drug interaction classified as: absorption

Source: DDInter

Bexarotene
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Dolutegravir
Severe
Database

Clinical effect not specified

Source: DDInter

Hydroxyurea
Severe
Database

.

Source: DDInter

Leflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Lomitapide
Severe
Database

Clinical effect not specified

Source: DDInter

Methadone
Severe
Database

Clinical effect not specified

Source: DDInter

Mipomersen
Severe
Database

Clinical effect not specified

Source: DDInter

Pentamidine
Severe
Database

.

Source: DDInter

Pexidartinib
Severe
Database

Clinical effect not specified

Source: DDInter

Ribavirin
Severe
Database

Not specified, but combination should not be used.

Should not be used together. Avoid combination.

Source: DDInter

Related guidelines

Other Unclassified drugs

Ask House about didanosine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team